Clinical and immunophenotypic profiles of cyclin D1-negative patients
| Patient no. . | Age (y)/ sex . | Sites of involvement . | Clinical stage . | LDH >normal . | PS > 1 . | Extranodal involvement >1 . | IPI . | CD5 . | CD10 . | CD23 . | sIgH . | sIgL . | Flow cytometry . | Therapy . | Effect . | Follow-up (mo) . | Outcome . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LN . | H/S . | BM . | PB . | Others . | CD20 . | Ig L . | ||||||||||||||||
| 1 | 48/F | + | −/− | + | − | IV A | + | − | − | LI | + | + | ND | − | λ | MC | CR | 56+ | Relapsed, alive in 2nd CR | |||
| 2 | 67/F | + | −/− | − | − | II A | + | − | − | LI | + | − | − | IgM | κ | CHOP | CR | 24+ | Alive in CR | |||
| 3 | 56/M | + | −/+ | + | + | IV A | − | − | + | LI | + | − | ND | ND | λ | MC | CR | 80+ | Alive in CR | |||
| 4 | 66/M | + | −/− | − | − | III A | − | − | − | LI | + | − | − | ND | λ | COP | NC | 69+ | Alive with disease | |||
| 5 | 73/M | − | −/− | − | − | Orbit | I E A | − | − | − | L | + | − | − | ND | κ | Radiation | CR | 13+ | Lost to follow-up in CR | ||
| 6 | 53/M | + | −/+ | − | − | WR, stomach, intestine | IV A | + | − | + | HI | + | − | − | ND | λ | MC | PR | 77 | Regrowth, DWD | ||
| 7 | 41/M | + | +/+ | + | + | IV B | − | − | + | LI | ND | ND | ND | ND | ND | Not given | — | — | Lost to follow-up | |||
| 8 | 67/F | + | −/− | − | − | III A | − | − | − | LI | + | ND | − | ND | ND | MC | PR | 12+ | Alive in PR | |||
| 9 | 74/F | + | −/− | − | − | Orbit | II E A | − | − | − | L | + | − | − | IgM | κ | Bright | Bright | Radiation | PR | 13+ | Alive in PR |
| 10 | 62/M | − | −/− | − | − | Orbit | I E A | − | − | − | L | + | − | − | IgM | λ | Bright | Bright | Radiation | CR | 58+ | Alive in CR |
| 11 | 60/M | + | −/− | − | − | II A | − | − | − | L | ND | ND | − | ND | ND | Radiation | CR | 79+ | Alive in CR | |||
| 12 | 61/F | + | +/+ | + | + | IV A | − | − | + | HI | + | ND | ND | IgM | κ | CHOP | PR | 12+ | Alive in PR | |||
| 13 | 62/M | + | −/+ | + | − | Small intestine, PE | IV A | − | − | + | HI | + | ND | − | ND | ND | MC | PR | 23+ | Alive in PR | ||
| 14 | 49/M | + | −/− | + | − | PE | IV A | − | − | + | LI | + | ND | − | ND | ND | CHOP | PR | 28+ | Regrowth, alive with disease | ||
| 15 | 62/M | + | −/− | − | − | III A | − | − | − | LI | + | − | + | IgM | λ | Dim | Dim | CY | NC | 49+ | Alive with disease | |
| 16 | 59/M | + | +/− | + | + | IV B | + | + | + | H | + | − | + | IgMD | λ | Dim | Bright | MC | CR | 60+ | Relapsed, alive with disease | |
| 17 | 53/M | + | −/− | + | − | IV A | − | + | − | LI | + | − | + | IgMD | λ | Bright | Bright | MC | CR | 81+ | Alive in CR | |
| 18 | 72/M | − | −/− | − | − | WR | I A | − | − | − | L | + | − | ND | IgM | κ | Radiation | CR | 83+ | Alive in CR | ||
| 19 | 74/F | + | −/− | + | − | IV A | − | − | + | HI | + | + | ND | IgM | κ | MC | CR | 150+ | Alive in CR | |||
| 20 | 54/M | + | −/− | + | + | IV A | − | − | − | L | + | − | + | IgMD | λ | Bright | Bright | CHOP | CR | 41+ | Alive in CR | |
| 21 | 57/F | − | −/− | − | − | Subcutis | I E A | − | − | − | L | ND | ND | ND | ND | ND | Resection + CHOP | CR | 47+ | Alive in CR | ||
| 22 | 32/M | + | +/+ | + | + | IV A | − | − | − | L | + | − | ND | IgMD | κ | MC | PR | 41+ | Alive with disease | |||
| 23 | 47/F | + | −/− | + | − | IV A | − | − | − | L | + | − | − | IgM | λ | Bright | Bright | MC | CR | 84 | Relapsed, DWD | |
| Patient no. . | Age (y)/ sex . | Sites of involvement . | Clinical stage . | LDH >normal . | PS > 1 . | Extranodal involvement >1 . | IPI . | CD5 . | CD10 . | CD23 . | sIgH . | sIgL . | Flow cytometry . | Therapy . | Effect . | Follow-up (mo) . | Outcome . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LN . | H/S . | BM . | PB . | Others . | CD20 . | Ig L . | ||||||||||||||||
| 1 | 48/F | + | −/− | + | − | IV A | + | − | − | LI | + | + | ND | − | λ | MC | CR | 56+ | Relapsed, alive in 2nd CR | |||
| 2 | 67/F | + | −/− | − | − | II A | + | − | − | LI | + | − | − | IgM | κ | CHOP | CR | 24+ | Alive in CR | |||
| 3 | 56/M | + | −/+ | + | + | IV A | − | − | + | LI | + | − | ND | ND | λ | MC | CR | 80+ | Alive in CR | |||
| 4 | 66/M | + | −/− | − | − | III A | − | − | − | LI | + | − | − | ND | λ | COP | NC | 69+ | Alive with disease | |||
| 5 | 73/M | − | −/− | − | − | Orbit | I E A | − | − | − | L | + | − | − | ND | κ | Radiation | CR | 13+ | Lost to follow-up in CR | ||
| 6 | 53/M | + | −/+ | − | − | WR, stomach, intestine | IV A | + | − | + | HI | + | − | − | ND | λ | MC | PR | 77 | Regrowth, DWD | ||
| 7 | 41/M | + | +/+ | + | + | IV B | − | − | + | LI | ND | ND | ND | ND | ND | Not given | — | — | Lost to follow-up | |||
| 8 | 67/F | + | −/− | − | − | III A | − | − | − | LI | + | ND | − | ND | ND | MC | PR | 12+ | Alive in PR | |||
| 9 | 74/F | + | −/− | − | − | Orbit | II E A | − | − | − | L | + | − | − | IgM | κ | Bright | Bright | Radiation | PR | 13+ | Alive in PR |
| 10 | 62/M | − | −/− | − | − | Orbit | I E A | − | − | − | L | + | − | − | IgM | λ | Bright | Bright | Radiation | CR | 58+ | Alive in CR |
| 11 | 60/M | + | −/− | − | − | II A | − | − | − | L | ND | ND | − | ND | ND | Radiation | CR | 79+ | Alive in CR | |||
| 12 | 61/F | + | +/+ | + | + | IV A | − | − | + | HI | + | ND | ND | IgM | κ | CHOP | PR | 12+ | Alive in PR | |||
| 13 | 62/M | + | −/+ | + | − | Small intestine, PE | IV A | − | − | + | HI | + | ND | − | ND | ND | MC | PR | 23+ | Alive in PR | ||
| 14 | 49/M | + | −/− | + | − | PE | IV A | − | − | + | LI | + | ND | − | ND | ND | CHOP | PR | 28+ | Regrowth, alive with disease | ||
| 15 | 62/M | + | −/− | − | − | III A | − | − | − | LI | + | − | + | IgM | λ | Dim | Dim | CY | NC | 49+ | Alive with disease | |
| 16 | 59/M | + | +/− | + | + | IV B | + | + | + | H | + | − | + | IgMD | λ | Dim | Bright | MC | CR | 60+ | Relapsed, alive with disease | |
| 17 | 53/M | + | −/− | + | − | IV A | − | + | − | LI | + | − | + | IgMD | λ | Bright | Bright | MC | CR | 81+ | Alive in CR | |
| 18 | 72/M | − | −/− | − | − | WR | I A | − | − | − | L | + | − | ND | IgM | κ | Radiation | CR | 83+ | Alive in CR | ||
| 19 | 74/F | + | −/− | + | − | IV A | − | − | + | HI | + | + | ND | IgM | κ | MC | CR | 150+ | Alive in CR | |||
| 20 | 54/M | + | −/− | + | + | IV A | − | − | − | L | + | − | + | IgMD | λ | Bright | Bright | CHOP | CR | 41+ | Alive in CR | |
| 21 | 57/F | − | −/− | − | − | Subcutis | I E A | − | − | − | L | ND | ND | ND | ND | ND | Resection + CHOP | CR | 47+ | Alive in CR | ||
| 22 | 32/M | + | +/+ | + | + | IV A | − | − | − | L | + | − | ND | IgMD | κ | MC | PR | 41+ | Alive with disease | |||
| 23 | 47/F | + | −/− | + | − | IV A | − | − | − | L | + | − | − | IgM | λ | Bright | Bright | MC | CR | 84 | Relapsed, DWD | |
LN, lymph node: H/S, hepatosplenic; BM, bone marrow; PB, peripheral blood; WR, Waldyer ring; PE, pleural effusion; PS, performance status; IPI, international prognostic index; L, low; LI, low-intermediate; HI, high-intermediate; H, high; ND, not done; sIg, surface immunoglobulin; IgL, immunoglobulin light chain; MC, multiple chemotherapy with doxorubicin; CHOP, cyclophosphamide, doxorubicin, vincristin, and predonisone; COP, cyclophosphamide, vincristin, and predonisone; CY, cyclophosphamide; CR, complete remission; PR, partial response; NC, no change; DWD, dead with disease.